Dako Eyes ImmunoCyt Test As Cystoscopy Alternative For Bladder Cancer
This article was originally published in The Gray Sheet
Executive Summary
Ongoing clinical trials will evaluate Dako Corp.'s urine-based ImmunoCyt test for possible use as a less invasive alternative to gold standard cystoscopy for monitoring of recurrent bladder cancer in some patients.